Myopia

Actress and Beauty Entrepreneur Peyton List Sets Her Sights on 2023 with Upgraded Vision from Life-Changing EVO ICL Lenses

Retrieved on: 
Wednesday, January 11, 2023

EVO is an FDA-approved vision correction lens designed for the correction/reduction of myopia with or without astigmatism.

Key Points: 
  • EVO is an FDA-approved vision correction lens designed for the correction/reduction of myopia with or without astigmatism.
  • View the full release here: https://www.businesswire.com/news/home/20230111005302/en/
    Peyton List, actress and entrepreneur, sets her sights on a new acting role without the hassles of eyeglasses and contact lenses thanks to her new EVO ICL lenses - a life-changing vision correction lens designed for the correction/reduction of myopia (nearsightedness) and astigmatism.
  • Recently, List had EVO lenses implanted by her doctor to upgrade her vision.
  • List went from struggling with the hassles of contact lenses, both on and off the film set, to having clear 20/20 vision following the EVO procedure.

Global Anti-blue Ray Myopia Lenses Market Expected to Garner $5,361.10 Million in the 2022-2030 Timeframe, Growing at 7.6% CAGR | Report [300-Pages] by Research Dive

Retrieved on: 
Thursday, January 12, 2023

NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Research Dive has added a new report to its offering titled, "Anti-blue Ray Myopia Lenses Market by Type (Single, Bifocal, Trifocal, and Others), Distribution Channel (Retail Stores, Hospital & Clinics, and E-Commerce Platforms), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2022-2030".

Key Points: 
  • As per the report, the global anti-blue ray myopia lenses market is predicted to grow at a stable CAGR of 7.6% in the 2022-2030 timeframe, thereby garnering $5,361.10 million by 2030.
  • Drivers: The anti-blue ray myopia lenses market is expected to witness a massive growth in its market size due to decreasing possibility of migraines and macular degeneration.
  • The report has divided the anti-blue ray myopia lenses market into certain segments based on type, distribution channel, and region.
  • By regional analysis, the anti-blue ray myopia lenses market in the Asia-Pacific region is expected to be the most profitable and rise with a CAGR of 6.6%.

Global Anti-blue Ray Myopia Lenses Market Expected to Garner $5,361.10 Million in the 2022-2030 Timeframe, Growing at 7.6% CAGR | Report [300-Pages] by Research Dive

Retrieved on: 
Thursday, January 12, 2023

NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Research Dive has added a new report to its offering titled, "Anti-blue Ray Myopia Lenses Market by Type (Single, Bifocal, Trifocal, and Others), Distribution Channel (Retail Stores, Hospital & Clinics, and E-Commerce Platforms), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2022-2030".

Key Points: 
  • As per the report, the global anti-blue ray myopia lenses market is predicted to grow at a stable CAGR of 7.6% in the 2022-2030 timeframe, thereby garnering $5,361.10 million by 2030.
  • Drivers: The anti-blue ray myopia lenses market is expected to witness a massive growth in its market size due to decreasing possibility of migraines and macular degeneration.
  • The report has divided the anti-blue ray myopia lenses market into certain segments based on type, distribution channel, and region.
  • By regional analysis, the anti-blue ray myopia lenses market in the Asia-Pacific region is expected to be the most profitable and rise with a CAGR of 6.6%.

22nd Hong Kong Eyewear Design Competition Winners Announced

Retrieved on: 
Tuesday, January 17, 2023

HONG KONG, Jan 17, 2023 - (ACN Newswire) - With this year's Avant Garde theme, the 22nd Hong Kong Eyewear Design Competition's winning pieces reflected the creativity, acute sense of style and boundless imagination of local designers.

Key Points: 
  • HONG KONG, Jan 17, 2023 - (ACN Newswire) - With this year's Avant Garde theme, the 22nd Hong Kong Eyewear Design Competition's winning pieces reflected the creativity, acute sense of style and boundless imagination of local designers.
  • The competition aims to encourage innovation and enhance the design quality of Hong Kong eyewear products, identify new talents and promote Hong Kong's creative products to international markets.
  • The award presentation held on 13 January was organised by the Hong Kong Trade Development Council (HKTDC) and the Hong Kong Optical Manufacturers Association, with the Hong Kong Polytechnic University and Hong Kong Design Institute as co-organisers.
  • Her eyewear design was inspired by the gear NFT video game characters use for survival.

The Worldwide Progressive Lenses Industry is Expected to Reach $38.6 Billion by 2027

Retrieved on: 
Tuesday, January 10, 2023

The global progressive lenses market is expected to grow at a CAGR of 4.37% during 2021-2027.

Key Points: 
  • The global progressive lenses market is expected to grow at a CAGR of 4.37% during 2021-2027.
  • Progressive lenses are multifocal lenses specifically for people needing corrective lenses to see distant and close objects.
  • In contrast to traditional bifocal or trifocal lenses, no visible lines separate the different fields in progressive lenses.
  • These advanced progressive designs have many advantages over standard progressive lenses as the Progressive lenses are slightly improved with each advancement released.

Vyluma to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 5, 2023

BRIDGEWATER, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, today announced it will present at the 41st annual J.P. Morgan Healthcare Conference, taking place January 9-12, 2023 in San Francisco, Calif.

Key Points: 
  • BRIDGEWATER, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, today announced it will present at the 41st annual J.P. Morgan Healthcare Conference, taking place January 9-12, 2023 in San Francisco, Calif.
    Vyluma Founder, Chairman, and Chief Executive Officer Navneet Puri, PhD will deliver a presentation on Thursday, January 12, 2023 at 11:30 a.m. PT in the Golden Gate room on the 32nd floor of the Westin St. Francis Hotel.
  • Dr. Puri will provide a company update, discuss significant advancements in 2022, and outline the company’s strategy and key priorities for 2023.
  • “With plans to submit a New Drug Application for NVK002 to the U.S. Food and Drug Administration as early as Q1 2023, we are significantly advancing on our commitment to help address the growing global myopia epidemic.
  • We look forward to participating in the 41st annual J.P. Morgan Healthcare Conference and discussing our plans for 2023 and beyond.”

Global Progressive Lenses Market Report 2022 to 2027 - Rise of E-commerce as a Preferred Distribution Channel Contributes Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023

The global progressive lenses market is expected to grow at a CAGR of 4.37% during 2021-2027.

Key Points: 
  • The global progressive lenses market is expected to grow at a CAGR of 4.37% during 2021-2027.
  • Progressive lenses are multifocal lenses specifically for people needing corrective lenses to see distant and close objects.
  • These advanced progressive designs have many advantages over standard progressive lenses as the Progressive lenses are slightly improved with each advancement released.
  • The rise in e-commerce as a distribution channel has contributed to the growing global demand for vision care products in the progressive lenses market.

Ophthalmic Lasers Global Market Report 2022: Increasing Regulatory Approvals for Ophthalmic Lasers Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 28, 2022

The "Ophthalmic Lasers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ophthalmic Lasers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The large prevalence of ophthalmic disorders around the world is adding to the growth of the ophthalmic lasers market.
  • The increasing prevalence of ophthalmic lasers in refractive error corrections is expected to aid the growth of the segment in the ophthalmic lasers market during the forecast period.
  • Thus the increasing necessity for surgeries involving ophthalmic lasers and increasing research and development in the healthcare department are known to propel the growth of the market in this region.

STAAR Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEO

Retrieved on: 
Monday, December 19, 2022

STAAR’s Board of Directors has appointed ophthalmic industry executive Thomas “Tom” G. Frinzi, current Board Chair of STAAR, to serve as President and CEO, effective January 1, 2023.

Key Points: 
  • STAAR’s Board of Directors has appointed ophthalmic industry executive Thomas “Tom” G. Frinzi, current Board Chair of STAAR, to serve as President and CEO, effective January 1, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20221219005204/en/
    Ophthalmic industry executive Tom Frinzi has been appointed President & CEO of STAAR Surgical, effective January 1, 2023.
  • Prior to joining STAAR, Ms. Mason served as CEO and in other senior executive roles at numerous innovative healthcare, life sciences, diagnostic technology, and medical device companies.
  • “Serving as CEO of STAAR Surgical has been the highlight of my career,” said Ms. Mason.

Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

Retrieved on: 
Tuesday, December 13, 2022

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for MydCombi™ ophthalmic spray. MydCombi™ is a drug-device combination product that comprises the company’s proprietary, first-in-class combination of tropicamide and phenylephrine for in-office pupil dilation (mydriasis), administered via the investigational Optejet® drug delivery technology.

Key Points: 
  • MydCombi™ is a drug-device combination product that comprises the company’s proprietary, first-in-class combination of tropicamide and phenylephrine for in-office pupil dilation (mydriasis), administered via the investigational Optejet® drug delivery technology.
  • The agency has assigned the resubmitted NDA a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of May 8, 2023.
  • The FDA also indicated that it is currently not planning to hold an advisory committee meeting to discuss the application.
  • Developed as a micro-formulation for use without anesthetic, Eyenovia believes Mydcombi will help improve the efficacy, tolerability, and efficiency of pharmacologic mydriasis.